Foghorn Therapeutics Inc. cotiza a 1.95 USD y tiene una capitalización bursátil de $116M. En los últimos 12 meses ha facturado $37M con un margen de flujo de caja libre del -278.7%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, an…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.10 | $-0.29 | $-0.37 |
| Estimado | $-0.25 | $-0.23 | $-0.31 | $-0.26 |
| Sorpresa | — | +56.5% | +6.5% | -42.3% |
| Métrica | FHTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -279.5% | -38.6% | -240.9% |
| Net Margin | -240.3% | -33.6% | -206.8% |
| FCF Margin | -278.7% | -13.9% | -264.9% |
| ROE | — | -40.4% | — |
| ROA | -37.5% | -32.0% | -5.5% |
| Current Ratio | 2.73 | 2.84 | -0.11 |
| Debt / Equity | — | 0.28 | — |